MedTrace Logo

Early Assessment of Anthracycline-induced Cardiotoxicity (CARDIOTOX)

NCT00195897 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2016-08-22

No results posted yet for this study

Summary

Anthracycline-based chemotherapy is a key point of the treatment of patients with Hodgkin's and non-Hodgkin's lymphomas. However, cumulative doses are limited by cardiotoxicity, resulting in a marked left ventricular function impairment that may lead to heart failure.

The standard clinical approach to monitoring for anthracycline cardiotoxicity is based on cardiac function monitoring using echocardiography or radionuclide angiography. The aim of this study is to evaluate the usefulness of biochemical markers of cardiac injury (troponin and NT-proBNP) and structural changes on cardiac MR in predicting anthracycline cardiotoxicity.

Conditions

Sponsors & Collaborators

  • Ligue contre le cancer, France

    collaborator OTHER

  • Centre Henri Becquerel

    lead OTHER

Principal Investigators

  • Alain Manrique, MD · Centre Henri Becquerel

  • Fabrice Jardin, MD · Centre Henri Becquerel

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00195897 on ClinicalTrials.gov